TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Genmab A/S
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Genmab announced positive Phase 3 trial results for EPKINLY, demonstrating significant clinical benefits in treating relapsed or refractory follicular lymphoma when combined with rituximab and lenalidomide, reducing disease progression risk by 79% and achieving a 95% overall response rate.

Insights
GMAB   positive

Successful Phase 3 trial results, FDA approval, significant clinical efficacy demonstrated in treating follicular lymphoma